COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Metabolic Pathways of GRA in Patients With Type 1 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03919617
Recruitment Status : Active, not recruiting
First Posted : April 18, 2019
Last Update Posted : June 9, 2020
REMD Biotherapeutics, Inc.
Information provided by (Responsible Party):
Jeremy Pettus, MD, University of California, San Diego

Brief Summary:
A pilot study for individuals with Type 1 Diabetes who are willing to add a GRA (Glucagon Receptor Antagonist) to their current Diabetes treatment regimen. There will be 10 study visits over the course of approximately 8 weeks, with 4 weeks of once weekly, subcutaneous GRA (REMD-477) injection. Testing includes 2 MRI scans, 2 glucose challenges, and 2 insulin withdrawal challenges along with physical assessments and vitals.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Mellitus Drug: REMD-477 Phase 1 Phase 2

Detailed Description:

This single-center, open label, multi-dose study is designed to elicit pilot data for a larger project. To accomplish the specific aims proposed, a single clinical trial will be conducted in which a maximum of 10 subjects with T1D, who are otherwise healthy, will be treated with REMD-477 for 4 weeks at a dose of 70mg (administered subcutaneously each week) with assessments done pre- and post-therapy. There is no comparator, nor is there any placebo in the study. In addition, there is no randomization, all subjects will receive the same 4 weeks of 70mg, once weekly dose of REMD-477.

There will be 10 study visits as outlined below:

  1. Screening - Complete medical history and physical exam, review of current medications, height/weight, vital signs, and fasting laboratory (blood and urine) tests.
  2. Visit 1 - Participants that meet screening criteria will be provided deuterated (heavy) water to consume overnight. Participants will ingest heavy water (2H2O) overnight in three equal doses (total 3ml/kg/body water). Participants will also undergo an MRI to evaluate hepatic (liver) fat content as well as total body composition.
  3. Visit 2 - Following Visit 1, participants will return to the clinic the next morning in the fasting state (8 hours) and after completing the heavy water consumption. Blood samples will be drawn for baseline amino acid levels as well as samples of serum, plasma, PBMCs, and extracted RNA stored for future metabolomics and genetic testing. Indirect calorimetry (IDC) will be performed to provide baseline resting energy expenditure (REE). Upon completion of IDC, participants will be given a 0.15 u/kg dose of rapid acting insulin and 15 minutes afterwards will ingest a 75g glucose and 25g fructose drink. Participants will then have samples collected over 6 hours to quantify isotope enrichment in plasma water as well as triglyceride isolated from VLDL. Repeat IDC will be performed 2 hours after consumption of the drink.
  4. Visit 3 - Insulin withdrawal challenge and injection #1 of REMD-477. Participants will suspend insulin delivery and remove insulin pump. Blood sugars and ketones will be monitored for up to 6 hours.
  5. Visit 4 - Injection #2 of REMD-477.
  6. Visit 5 - Injection #3 of REMD-477.
  7. Visit 6 - Injection #4 of REMD-477.
  8. Visit 7 - Provide heavy water and complete MRI scan #2.
  9. Visit 8 - Repeat all Visit 2 procedures.
  10. Visit 9 - Repeat all Visit 3 procedures.
  11. Visit 10 - Safety follow-up visit that includes physical exam, vitals, blood and urine sample collection.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Single-center, open label, multi-dose study.
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: The Effects of a Glucagon Receptor Antagonist (GRA) on Non-Glucose Metabolic Pathways in Patients With Type 1 Diabetes (Pilot Study)
Actual Study Start Date : July 1, 2019
Actual Primary Completion Date : March 31, 2020
Estimated Study Completion Date : August 31, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arm Intervention/treatment
Experimental: Open-Label REMD-477 Drug: REMD-477
4-Week, open-label, once weekly subcutaneous injection with 70mg REMD-477.

Primary Outcome Measures :
  1. Change in Beta-hydoxybutyrate (BHB) Level [ Time Frame: 4-Weeks ]
    The change from baseline in peak BHB production as measured by the insulin withdrawal challenge.

  2. Rate of De Novo Lipogenesis (DNL) [ Time Frame: 4-Weeks ]
    Change from baseline in disrupted glucagon signaling as measured by the glucose challenge and deuterated water ingestion.

  3. Rate of Hepatic Steatosis [ Time Frame: 4-Weeks ]
    Changes from baseline in hepatic steatosis as measured by the glucose challenge and deuterated water ingestion.

  4. Rate of Resting Energy Expenditure (REE) [ Time Frame: 4-Weeks ]
    Change from baseline REE as measured by the glucose challenge and deuterated water ingestion.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Men and women between the ages of 18 and 65 years old, inclusive, at the time of screening;
  2. Females of non-child bearing potential must be ≥ 1 year post-menopausal or documented as being surgically sterile. Females of child bearing potential must agree to use two methods of contraception during the entire study and for an additional 3 months after the end of dosing with the investigational product;
  3. Male subjects must be willing to use clinically acceptable method of contraception during the entire study and for an additional 6 months after the end of the treatment period;
  4. Diagnosed with Type 1 diabetes based on clinical history or as defined by the current American Diabetes Association (ADA) criteria for > 5 years;
  5. Treatment with a stable insulin regimen (< 1u/kg per day) for at least 8 weeks before screening with continuous subcutaneous insulin infusion (CSII) via an insulin pump;
  6. HbA1c ≤ 10 % at screening;
  7. A minimum weight of 50kg;
  8. Able to provide written informed consent approved by an Institutional Review Board (IRB).

Exclusion Criteria:

  1. History or evidence of clinically-significant disorder or condition that, in the opinion of the Investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion;
  2. History of pancreatitis, medullary thyroid carcinoma and/or liver disease;
  3. Clinically significant diagnosis of anemia;
  4. Body Mass Index (BMI) < 18.5 kg/m2 and/or weight less than 50kg;
  5. Whole blood donation of 1 pint (500 mL) within 8 weeks prior to Screening. Donations of plasma, packed RBCs, platelets or quantities less than 500 mL are allowed at investigator discretion;
  6. Current or recent (within 1 month of screening) use of diabetes medications other than insulin;
  7. Women who are pregnant or lactating/breastfeeding;
  8. Subjects for whom an MRI is contraindicated;
  9. Unable or unwilling to follow the study protocol or who are non-compliant with screening appointments or study visits;
  10. Any other condition(s) that might reduce the chance of obtaining study data, or that might cause safety concerns, or that might compromise the ability to give truly informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03919617

Layout table for location information
United States, California
UC San Diego Altman Clinical & Translational Research Institute
La Jolla, California, United States, 92037
Sponsors and Collaborators
University of California, San Diego
REMD Biotherapeutics, Inc.
Layout table for additonal information
Responsible Party: Jeremy Pettus, MD, Assistant Clinical Professor, University of California, San Diego Identifier: NCT03919617    
Other Study ID Numbers: UC-MEDJP-02
First Posted: April 18, 2019    Key Record Dates
Last Update Posted: June 9, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs